Bibliographic Details
| Title: |
Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trialsResearch in context |
| Authors: |
Subodh Verma, Meena Bhatta, Melanie Davies, John E. Deanfield, W. Timothy Garvey, Camilla Jensen, Kristian Kandler, Robert F. Kushner, Domenica M. Rubino, Mikhail N. Kosiborod |
| Source: |
EClinicalMedicine, Vol 55, Iss , Pp 101737- (2023) |
| Publisher Information: |
Elsevier, 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Medicine (General) |
| Subject Terms: |
C-reactive protein, Cardiovascular risk factors, Semaglutide, Obesity, Type 2 diabetes, Weight loss, Medicine (General), R5-920 |
| More Details: |
Summary: Background: Inflammation is a key driver of atherosclerotic cardiovascular disease. C-reactive protein (CRP), an established biomarker of inflammation, is commonly elevated in people with overweight/obesity. Methods: STEP 1, 2, and 3 were 68-week, placebo-controlled trials of semaglutide for weight management in participants with overweight/obesity, with (STEP 2) or without (STEP 1 and 3) type 2 diabetes. Change in serum CRP from baseline to week 68 was assessed as a prespecified secondary endpoint for semaglutide 2.4 mg versus placebo (STEP 1, 2, and 3) and versus semaglutide 1.0 mg (STEP 2). Post hoc assessments included change in CRP by baseline characteristics (bodyweight, body mass index [BMI], glycaemic status, CRP concentration); change in CRP-defined cardiovascular risk category (3 mg/L [high]); and correlation between change in CRP and change in bodyweight, waist circumference, fasting serum insulin (STEP 1 and 3), fasting plasma glucose, and homeostatic model assessment of insulin resistance (HOMA-IR). Findings: The trials took place from June through November 2018 (STEP 1 and 2) and from August 2018 to April 2020 (STEP 3). In all trials, semaglutide 2.4 mg reduced CRP at week 68 versus placebo (estimated treatment difference [ETD; 95% CI] −44% [–49 to −39] in STEP 1, –39% [–46 to −30] in STEP 2, and –48% [–55 to −39] in STEP 3; all p |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2589-5370 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S2589537022004667; https://doaj.org/toc/2589-5370 |
| DOI: |
10.1016/j.eclinm.2022.101737 |
| Access URL: |
https://doaj.org/article/60feb89664bd496d9129a6ab9fd90750 |
| Accession Number: |
edsdoj.60feb89664bd496d9129a6ab9fd90750 |
| Database: |
Directory of Open Access Journals |
